BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 27305912)

  • 1. Proteomic modulation in breast tumors after metformin exposure: results from a "window of opportunity" trial.
    Kalinsky K; Zheng T; Hibshoosh H; Du X; Mundi P; Yang J; Refice S; Feldman SM; Taback B; Connolly E; Crew KD; Maurer MA; Hershman DL
    Clin Transl Oncol; 2017 Feb; 19(2):180-188. PubMed ID: 27305912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of reverse phase protein array for molecular classification of breast cancer.
    Negm OH; Muftah AA; Aleskandarany MA; Hamed MR; Ahmad DA; Nolan CC; Diez-Rodriguez M; Tighe PJ; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2016 Jan; 155(1):25-35. PubMed ID: 26661092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytologic evaluation of cyclin D1 expression in primary breast carcinoma.
    Park K; Han S; Kim HY; Ko I
    Cancer; 2001 Jun; 93(3):211-5. PubMed ID: 11391609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.
    Dowling RJ; Niraula S; Chang MC; Done SJ; Ennis M; McCready DR; Leong WL; Escallon JM; Reedijk M; Goodwin PJ; Stambolic V
    Breast Cancer Res; 2015 Mar; 17(1):32. PubMed ID: 25849721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.
    Hadad S; Iwamoto T; Jordan L; Purdie C; Bray S; Baker L; Jellema G; Deharo S; Hardie DG; Pusztai L; Moulder-Thompson S; Dewar JA; Thompson AM
    Breast Cancer Res Treat; 2011 Aug; 128(3):783-94. PubMed ID: 21655990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer.
    Luhtala S; Staff S; Tanner M; Isola J
    Tumour Biol; 2016 Jul; 37(7):9813-23. PubMed ID: 26810187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidiabetic drug metformin induces apoptosis in human MCF breast cancer via targeting ERK signaling.
    Malki A; Youssef A
    Oncol Res; 2011; 19(6):275-85. PubMed ID: 21776823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple protein analysis of formalin-fixed and paraffin-embedded tissue samples with reverse phase protein arrays.
    Assadi M; Lamerz J; Jarutat T; Farfsing A; Paul H; Gierke B; Breitinger E; Templin MF; Essioux L; Arbogast S; Venturi M; Pawlak M; Langen H; Schindler T
    Mol Cell Proteomics; 2013 Sep; 12(9):2615-22. PubMed ID: 23653450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial.
    Hadad SM; Coates P; Jordan LB; Dowling RJ; Chang MC; Done SJ; Purdie CA; Goodwin PJ; Stambolic V; Moulder-Thompson S; Thompson AM
    Breast Cancer Res Treat; 2015 Feb; 150(1):149-55. PubMed ID: 25682077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
    Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
    Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial mesenchymal transition in early invasive breast cancer: an immunohistochemical and reverse phase protein array study.
    Aleskandarany MA; Negm OH; Green AR; Ahmed MA; Nolan CC; Tighe PJ; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2014 Jun; 145(2):339-48. PubMed ID: 24771047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53.
    Guo LL; Gao P; Wu YG; Jian WC; Hao CY; Li H; Lin XY
    Arch Med Res; 2007 Nov; 38(8):846-52. PubMed ID: 17923265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: Relation with clinicopathologic characteristics and with p53 expression and estrogen receptor status.
    Oh YL; Choi JS; Song SY; Ko YH; Han BK; Nam SJ; Yang JH
    Pathol Int; 2001 Feb; 51(2):94-9. PubMed ID: 11169147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
    Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
    Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer.
    Campagnoli C; Berrino F; Venturelli E; Abbà C; Biglia N; Brucato T; Cogliati P; Danese S; Donadio M; Zito G; Pasanisi P
    Clin Breast Cancer; 2013 Dec; 13(6):433-8. PubMed ID: 24267731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.
    Feldt M; Bjarnadottir O; Kimbung S; Jirström K; Bendahl PO; Veerla S; Grabau D; Hedenfalk I; Borgquist S
    J Transl Med; 2015 Apr; 13():133. PubMed ID: 25925673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin and erlotinib synergize to inhibit basal breast cancer.
    Lau YK; Du X; Rayannavar V; Hopkins B; Shaw J; Bessler E; Thomas T; Pires MM; Keniry M; Parsons RE; Cremers S; Szabolcs M; Maurer MA
    Oncotarget; 2014 Nov; 5(21):10503-17. PubMed ID: 25361177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel biomarker C6orf106 promotes the malignant progression of breast cancer.
    Jiang G; Zhang X; Zhang Y; Wang L; Fan C; Xu H; Miao Y; Wang E
    Tumour Biol; 2015 Sep; 36(10):7881-9. PubMed ID: 25953261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of combined analysis of cyclin D1 and estrogen receptor status in breast cancer patients.
    Hwang TS; Han HS; Hong YC; Lee HJ; Paik NS
    Pathol Int; 2003 Feb; 53(2):74-80. PubMed ID: 12588434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High nuclear grade, frequent mitotic activity, cyclin D1 and p53 overexpression are associated with stromal invasion in mammary intracystic papillary carcinoma.
    Zhang C; Zhang P; Hao J; Quddus MR; Steinhoff MM; Sung CJ
    Breast J; 2005; 11(1):2-8. PubMed ID: 15647071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.